CYTODROX Capsules (Hydroxyurea)

Table of Content

Composition

CYTODROX Capsules
Each capsule contains:
Hydroxyurea USP …......... 500 mg
Approved colours used in empty capsule

Indications

  • Melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary
  • Concomitantly with irradiation therapy in the local control of cervical cancer and primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip

Dosage and Administration

Solid tumours

  • Intermittent Therapy: 80 mg/kg administered orally as a single dose every third day
  • Continuous Therapy: 20 to 30 mg/kg administered orally as a single dose daily
  • Concomitant Therapy with Irradiation: Carcinoma of the head and neck 80 mg/kg administered orally as a single dose every third day

Resistant Chronic Myelocytic Leukemia

Continuous therapy (20-30 mg/kg administered orally as a single dose daily)

Contraindications

  • Marked bone marrow depression, i.e., leucopenia (<2500 WBC) or thrombocytopenia (<100,000), or severe anaemia.
  • Previous hypersensitivity to hydroxyurea or any other component of its formulation.

Most Common Adverse Reactions

Bone marrow suppression (leucopenia, anaemia, and thrombocytopenia), gastrointestinal symptoms (stomatitis, anorexia, nausea, vomiting, diarrhoea, constipation) and dermatological reactions (maculopapular rash, skin ulceration, dermatomyositis-like skin changes, peripheral and facial erythema)

Storage

Store in a cool dry place. Protect from moisture.

Packaging Information

CYTODROX Capsules: Strip of 10 capsules